CervoMed Inc. (Nasdaq: CRVO) — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. The unaudited statements reflect EIP Pharmaceuticals as the accounting acquirer in the August 16, 2023 reverse recapitalization. Accordingly, prior-period results are EIP’s historical results and are not fully comparable with the post-merger combined company.
Business context and operating results
CervoMed is a clinical-stage biotechnology company developing neflamapimod, an oral brain-penetrant p38α inhibitor. Its lead program is a Phase 2b trial in dementia with Lewy bodies (DLB). The company has no approved products and reported no product-sales revenue; reported revenue is from a National Institute on Aging (NIA) research grant.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Grant revenue | $1.53 million | $0 | $4.65 million | $0 |
| Research and development expense | $1.79 million | $0.33 million | $5.58 million | $0.96 million |
| General and administrative expense | $2.41 million | $0.57 million | $4.40 million | $1.58 million |
| Operating loss | $2.68 million | $0.90 million | $5.33 million | $2.54 million |
| Net income (loss) | $2.15 million | $(0.88) million | $0.19 million | $(4.28) million |
| Operating cash flow | Not provided by quarter | $(4.91) million | $(1.88) million |
Operating margins are not a meaningful indicator for this pre-commercial company; grant revenue does not represent product sales. Despite positive reported net income, operations remained loss-making. Net income included a noncash $4.78 million gain from the fair-value remeasurement of convertible notes immediately before their conversion in the merger. The nine-month noncash gain was $5.42 million. The filing’s diluted per-share figures are negative despite positive basic figures because the diluted calculation adjusts for the convertible-note fair-value change; consult the statement and EPS note when assessing per-share performance.
Financial position, liquidity and financing
- At September 30, 2023, cash and cash equivalents were $10.42 million, versus $4.09 million at December 31, 2022; total assets were $12.04 million.
- Total liabilities were $2.46 million, including $0.53 million of accounts payable, $0.55 million of deferred grant revenue and $1.38 million of accrued expenses. Convertible notes were zero at quarter-end after conversion into equity in connection with the merger.
- Stockholders’ equity was $9.57 million, compared with a $33.29 million deficit at year-end 2022. The change principally reflects conversion of preferred stock and notes and the merger recapitalization.
- Nine-month financing cash flow was $11.24 million, principally reflecting $11.89 million of net assets assumed in the reverse recapitalization, offset by transaction costs, plus $0.81 million of stock-sale proceeds. These financing and noncash recapitalization items boosted reported cash and equity.
- The company received $5.2 million of the $21.0 million NIA grant by September 30, with approximately $15.8 million remaining; $0.5 million received in advance was deferred revenue. Grant funding is tied to eligible costs and future-year availability and progress requirements.
- A $2.5 million line of credit was undrawn. It bears a variable rate and is secured by the CEO’s personal assets.
Management said cash on hand plus remaining NIA grant funding was expected to cover operating and capital needs for at least 12 months from issuance of the statements, and elsewhere estimated funding through the end of 2024. The filing also states that losses, negative operating cash flows and future capital needs raise substantial doubt about the company’s ability to continue as a going concern. Additional financing will be needed to advance development; it may not be available on acceptable terms and could dilute shareholders or require concessions.
Material changes, outlook and key risks
- Merger and capital structure: The August 16 merger with EIP was accounted for as a reverse recapitalization; CervoMed adopted its current name and completed a 1-for-1.5 reverse stock split. EIP holders received most of the post-merger ownership. At September 30, 5,674,354 common shares were outstanding, alongside 495,995 merger-related pre-funded warrants with a $0.001 exercise price. The cover reports 5,674,520 shares outstanding as of November 9.
- Expense growth: R&D increased as the DLB Phase 2b trial began; G&A rose with public-company costs and increased headcount following the merger. Nine-month operating expenses increased to $9.99 million from $2.54 million.
- Clinical outlook: The RewinD-LB Phase 2b trial is planned for 160 early-stage DLB patients, randomized to 40 mg neflamapimod or placebo three times daily for 16 weeks, followed by 32 weeks of open-label treatment for completers. Management expected enrollment completion in the first half of 2024 and initial placebo-controlled results in the second half of 2024. The NIA grant supports the study; management said results are intended to inform Phase 3 design and that the general framework had been discussed with the FDA.
- Drug-development risks: The Phase 2b results are uncertain, enrollment and trial costs may vary, and the company depends on third parties for research, clinical execution and manufacturing. Neflamapimod remains investigational. The FDA partial clinical hold limits U.S. dosing to no more than 40 mg three times daily for patients weighing at least 60 kg; management said its current plans do not require exceeding that dose. The filing also describes historical liver-enzyme elevations at higher doses and other reported adverse events.
- Accounting and controls: The company restated previously reported first- and second-quarter 2023 information after merger costs were incorrectly expensed instead of capitalized against merger proceeds. Management concluded disclosure controls were ineffective and identified material weaknesses involving complex transactions and expense-account review. Remediation was expected to begin in Q4 2023; effectiveness had not yet been established.
- Contingency: A lawsuit brought by former predecessor-company CEO Paul Feller remains unresolved; trial was continued to April 24, 2024. The company says it is defending the matter but cannot estimate a possible loss; an adverse resolution could materially affect financial position, results or cash flows.
- License obligations: The Vertex license carries potential regulatory and sales milestones totaling up to approximately $117 million, plus royalties on net sales. No payments were made during the quarter or nine-month period.
- Other assets and risks: The legacy Diffusion TSC program was paused, and the company was seeking an acquirer or licensee; none had been identified as of the filing. Other disclosed risks include grant funding availability, dilution and financing, intellectual-property protection, Nasdaq listing, and merger integration.
Important facts for investors to verify
- Whether Phase 2b enrollment and the stated results timetable were achieved, and what the complete trial data show.
- How much of the NIA grant has been received, whether future-year funding conditions are met, and whether cash runway remains consistent with management’s estimate.
- Whether the identified control weaknesses were remediated and whether subsequent filings report further accounting corrections.
- The status and potential financial exposure of the Feller litigation and any material developments in the TSC asset process.
- Current fully diluted share count, including pre-funded warrants, options and other potential equity issuance, and any new financing terms.
- Any changes to the FDA hold or dosing conditions, clinical safety findings, Vertex obligations, or management’s going-concern assessment.